Early in 2006 Sutent became the first therapy to gain initial and simultaneous approval by the FDA for two different types of cancer—advanced renal cell carcinoma and gastrointestinal stromal tumor, the latter after disease progression on or resistance to Gleevec.
Sutent works by blocking two basic processes, proliferation and angiogenesis, that cause tumors to grow and spread. Pfizer is studying Sutent as a potential treatment for various solid tumors, among them breast cancer, non-small cell lung cancer, liver cancer, prostate cancer and advanced colorectal cancer.
Get the Flash Player to see this rotator.
Gleevec is a trademark of Novartis AG.